Despite a temporary halt of an experimental spinal cord implant trial following a patient death, InVivo Therapeutics is doubling down and focusing its financial resources on the treatment by initiating a strategic restructuring that includes cutting nearly 40 percent of its workforce.
The U.S. FDA turned down Acorda Therapeutics’ New Drug Application for Inbrija, which was being evaluated for OFF periods in Parkinson’s disease.
AstraZeneca is to receive up to $400 million from Takeda after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson’s disease.
PACIFIC Communications, the West Coast’s largest healthcare communications agency, announced the return of Associate Creative Director/Copy Kent Sewell.
A large study of a new type of cholesterol medicine from Merck & Co. Inc. found it cut the risk of heart attack and death by a modest 9 percent, while causing a build up of the drug in fat tissue, leaving its commercial future uncertain.
Outcome Health, which provides health intelligence in moments of care to improve patient outcomes, announced the hiring of its first Chief Engineering Officer, Nandini Ramani.
Bristol-Myers Squibb Co. and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers’ immuno-oncology drug, Opdivo with the Japanese company’s experimental drug in patients with breast and bladder cancers.
The U.S. FDA is stepping up efforts to better regulate an emerging field of medicine that holds significant promise for curing some of the most troubling diseases by using the body’s own cells.
AstraZeneca forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting.